Further studies have shown that by the CRISPR-mediated HPRT gene inactivation approach used in mice [31], human-chromosome-transplanted iPSCs can be obtained from patients affected by other diseases mapping to the X chromosome such as Duchenne muscular dystrophy (DMD). This evidence concerns the gene HPRT1 and Duchenne muscular dystrophy.